SGLT-2 inhibitors (SGLT-2i) are a class of drugs originally developed for diabetes treatment but have shown potential anticancer effects. This review explores the mechanisms and therapeutic potential of SGLT-2i in various cancers. SGLT-2i work by inhibiting glucose reabsorption in the kidneys, reducing glucose availability to cancer cells, and disrupting metabolic pathways essential for tumor growth. They also induce cell cycle arrest, apoptosis, and inhibit angiogenesis. SGLT-2i have been shown to reduce glucose uptake in cancer cells, suppress tumor growth, and enhance the effectiveness of other cancer treatments. The expression of SGLT-2 is elevated in many cancers, including hepatocellular, pancreatic, breast, lung, and cervical cancers, suggesting its role in tumor progression. Different SGLT-2i have varying metabolic pathways and effects on cancer cells. Clinical studies indicate that SGLT-2i may be a promising adjunct to conventional cancer therapies. However, further research is needed to determine the optimal dosages, administration routes, and combinations with existing anticancer drugs. The review highlights the potential of SGLT-2i as a repurposed drug for cancer treatment, emphasizing the need for more clinical trials to evaluate their safety and efficacy in cancer patients.SGLT-2 inhibitors (SGLT-2i) are a class of drugs originally developed for diabetes treatment but have shown potential anticancer effects. This review explores the mechanisms and therapeutic potential of SGLT-2i in various cancers. SGLT-2i work by inhibiting glucose reabsorption in the kidneys, reducing glucose availability to cancer cells, and disrupting metabolic pathways essential for tumor growth. They also induce cell cycle arrest, apoptosis, and inhibit angiogenesis. SGLT-2i have been shown to reduce glucose uptake in cancer cells, suppress tumor growth, and enhance the effectiveness of other cancer treatments. The expression of SGLT-2 is elevated in many cancers, including hepatocellular, pancreatic, breast, lung, and cervical cancers, suggesting its role in tumor progression. Different SGLT-2i have varying metabolic pathways and effects on cancer cells. Clinical studies indicate that SGLT-2i may be a promising adjunct to conventional cancer therapies. However, further research is needed to determine the optimal dosages, administration routes, and combinations with existing anticancer drugs. The review highlights the potential of SGLT-2i as a repurposed drug for cancer treatment, emphasizing the need for more clinical trials to evaluate their safety and efficacy in cancer patients.